Financial Performance - The net profit attributable to the parent company for 2023 is CNY 42,497,439.19, while the consolidated undistributed profit is CNY -84,417,293.52[5] - The company will not distribute profits for 2023 due to existing undistributed losses and plans to cancel repurchased shares to enhance earnings per share[5] - The company's operating revenue for 2023 was CNY 695,175,319.22, a decrease of 3.04% compared to CNY 716,948,756.64 in 2022[23] - The net profit attributable to shareholders for 2023 was CNY 42,497,439.19, down 37.53% from CNY 68,024,427.15 in 2022[23] - The basic earnings per share for 2023 was CNY 0.31, a decline of 36.73% from CNY 0.49 in 2022[25] - The company's net cash flow from operating activities improved by CNY 116,115,977.11 compared to the previous year, although it remained negative[27] - The company’s net profit excluding non-recurring gains and losses was 35.67 million yuan, a decrease of 33.74% year-on-year[37] - The company reported a revenue of ¥695.18 million for the current period, a decrease of 3.04% compared to ¥716.95 million in the same period last year[130] - Operating costs decreased by 4.35% to ¥335.32 million from ¥350.57 million year-on-year, resulting in a gross margin of 51.76%, an increase of 0.66 percentage points[131] Audit and Compliance - A standard unqualified audit report was issued by Dahua Certified Public Accountants for the financial statements[5] - The company is committed to ensuring the accuracy and completeness of its financial reports, as stated by its management[5] - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7] - The company has not experienced any violations of decision-making procedures regarding external guarantees[8] Research and Development - Research and development expenses accounted for 32.72% of operating revenue, an increase of 8.01 percentage points from 24.71% in 2022[25] - The company is investing in artificial intelligence technology to develop its own large models and improve existing AI products[26] - The company applied for 40 new invention patents and received authorization for 17 patents during the reporting period, totaling 45 authorized invention patents by the end of the period[39] - The company’s total number of R&D personnel increased by 2.6% to 705 by the end of the reporting period[38] - The company has accumulated 45 authorized invention patents and 903 software copyrights in the field of medical information technology as of the end of the reporting period[114] Market Position and Strategy - The company has maintained its leading position in the electronic medical record (EMR) market for nine consecutive years, according to IDC's report on the Chinese EMR market share in 2022[49] - In the medical big data sector, the company achieved a market share of 8.8% in 2022, ranking first for the fourth consecutive year[50] - The company has over 1,600 hospital clients, including more than 600 top-tier hospitals, representing over 25% of all top-tier hospitals in China[75] - The company ranks first in the medical big data solution market in China as of 2022, according to IDC[78] - The company is focused on integrating various medical data systems to enhance the overall quality of healthcare services provided[56] Technology and Innovation - The company is focusing on enhancing its core technologies, with 30 core technologies developed, including real-time data transmission and storage technology[39] - The company has developed the Jiahe Medical Large Model, which supports nearly 20 medical tasks, improving the efficiency and quality of medical services through intelligent diagnosis and treatment processes[45] - The company is exploring the application of large model technology in healthcare scenarios, including health consultations and clinical research design[48] - The integration of new technologies such as big data, AI, cloud computing, and IoT is revolutionizing the medical information industry, enhancing efficiency and effectiveness in data management and patient care[72] Risks and Challenges - The company has detailed potential risks in the report, which investors should consider[4] - The company faces risks related to technology upgrades and potential core technology leaks, which could impact its competitive advantage and profitability[118] - The company is exposed to seasonal fluctuations in performance, with significant revenue recognition occurring in the second half of the year, particularly in Q4[120] - The company’s ability to recover accounts receivable is weak, posing risks of bad debt and cash flow deterioration[121] Employee and Management - The total number of employees in the parent company is 45[200] - The total number of employees in major subsidiaries is 2,005[200] - The combined total number of employees is 2,050[200] - The number of technical personnel is 1,677, representing approximately 81.7% of total employees[200] - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to CNY 6.061 million[187] Future Outlook - The company plans to focus on enhancing its product layout and competitive advantage by accelerating research and development projects[26] - The company is committed to developing AI-driven solutions that create a closed-loop smart medical service from pre-diagnosis to post-treatment[61] - The company is focusing on expanding its market presence through innovative product offerings and strategic partnerships in the healthcare sector[98] - The future outlook remains positive, with a focus on sustainable growth and innovation in the healthcare sector[179]

大华会计师事务所(特殊普通合伙) 《关于嘉和美康（北京）科技股份有限公司 2023 年年度报告的信息披露监管问询函》的回复 大华核字[2024]0011013479 号 大 华 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Da Hua Certified PublicAccountants（Special General Partnership） 大华会计师事务所(特殊普通合伙) 《关于嘉和美康（北京）科技股份有限公司 2023 年年度报告的信息披露监管问询函》的回复 目 录 页 次 一、 大华会计师事务所(特殊普通合伙)《关于嘉和 美康（北京）科技股份有限公司 2023 年年度 报告的信息披露监管问询函》的回复 1-39 大华会计师事务所（特殊普通合伙） 北京市海淀区西四环中路 16 号院 7 号楼 12 层[100039] 电话：86(10)58350011 传真：86(10)58350006 www.dahua-cpa.com 大华会计师事务所(特殊普通合伙) 《关于嘉和美康（北京）科技股份有限公司 2023 年年度报告的信息披露监管问询函》的回复 大华核字[2024]0011013479 号 ...

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [2] Core Views - The company has faced performance pressure in 2023 due to the rhythm of hospital procurement, with a revenue of 695 million yuan, a year-on-year decrease of 3.04%, and a net profit of 42 million yuan, down 37.53% [5] - In Q1 2024, the company reported a revenue of 123 million yuan, a year-on-year increase of 14.00%, and significantly reduced losses compared to the same period last year [6] - The company is increasing its R&D investment, which accounted for 32.72% of revenue in 2023, up 8.01 percentage points year-on-year, enhancing its competitive advantage [7] - The company is exploring deep applications of artificial intelligence in the medical field, having developed a large medical model that supports various medical tasks [8] Financial Summary - In 2023, the company achieved a revenue of 695 million yuan, with a projected revenue of 838 million yuan in 2024, representing a year-on-year growth of 20.6% [9] - The net profit is expected to rebound significantly in 2024, reaching 111 million yuan, a year-on-year increase of 160.4% [10] - The company’s gross margin is projected to remain stable, with slight improvements expected over the next few years [9][10] R&D and Market Position - The company is focusing on the development of intelligent diagnosis and treatment technologies based on AI and big data, aligning with national policies promoting smart hospital construction [7][8] - The company has become the largest shareholder of Ande Medical Intelligence, which may enhance its capabilities in AI-assisted diagnosis and treatment decision-making [8] Earnings Forecast - The company is expected to achieve revenues of 838 million yuan in 2024, 1.015 billion yuan in 2025, and 1.244 billion yuan in 2026, with corresponding net profits of 111 million yuan, 135 million yuan, and 157 million yuan respectively [10][14]

证券代码：688246 证券简称：嘉和美康 公告编号：2024-031 嘉和美康（北京）科技股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 25 | | --- | --- | | 普通股股东人数 | 25 | | 2、出席会议的股东所持有的表决权数量 | 63,720,056 | | 普通股股东所持有表决权数量 | 63,720,056 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 46.3192 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 46.3192 | | （%） | | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 （一） 股东大会召开的时间：2024 年 05 月 21 日 ...

| --- | --- | |---------------------------|------------| | | | | ＃市场 数 据 市场数据日期 | 2024-05-17 | | 收盘价（元） | 23.16 | | 总股本（百万股） | 138.57 | | 流通股本（百万股） | 101.94 | | 净资产（百万元） | 1816.53 | | 总资产（百万元） | 2692.1 | | 每股净资产(元 ) | 13.11 | jiangjialin@xyzq.com.cn | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------|--------|--------|-------|--------| | ＄ 会计 zy 年 c 度 wzb\| 主要财务指标＄ | 2023 | 2024E | 2025E | 2026E | | 营业收入 ( 百万元 ) | 695 | 834 | 1026 | 1241 | | 同比 ...

投资者应注意，在法律允许的情况下，本公司及其本公司的关联机构可能会持有报告中涉及的公司所发行的 证券并进行交易，并可能为这些公司正在提供或争取提供投资银行、财务顾问和金融产品等各种金融服务。 本公司及其本公司的关联机构或个人可能在本报告公开发布之前已经使用或了解其中的信息。 24 年 Q1 收入显著改善，医疗大模型产品落地良好 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------|-------|-------|-------|------------|--------------------------------------------------|--------|-------------------------|-------|--------| | 盈利预测表 \n[Table_Finance2] 资产负债表 单位 \n会计年度 2023 2024E 2025 ...

华泰联合证券有限责任公司 关于嘉和美康（北京）科技股份有限公司 2023 年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司简称：嘉和美康 | | --- | --- | | 保荐代表人姓名：孔祥熙 | 联系电话：010-56839300 | | 保荐代表人姓名：王琛 | 联系电话：010-56839300 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为嘉和美康（北京）科技股份有限 公司（以下简称"嘉和美康"、"公司"或"发行人"）首次公开发行股票的保 荐机构，对嘉和美康进行持续督导，并出具 2023 年度（以下简称"报告期"）持 续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 二、重大风险事项 公司面临的风险因素主要包括： （一）核心竞争力风险 1、因技术升级导致的产品迭代风险 保荐机构核查发现，公司股东存在未能及时履行承诺的情形，具体如下： 公司股东咸宁市凯旋机会成长基金（有限合伙）（以下简称"凯旋成长"） 于公司首发上市 ...

证券代码：688246 证券简称：嘉和美康 嘉和美康（北京）科技股份有限公司 2023 年年度股东大会会议资料 2024 年 5 月 21 日 | 2023 年年度股东大会会议须知 | | | 2 | | --- | --- | --- | --- | | 2023 年年度股东大会会议议程 | | | 4 | | 2023 年年度股东大会会议议案 | | | 6 | | 议案一：关于公司 | 2023 | 年度董事会工作报告的议案 | 6 | | 议案二：关于公司 | 2023 | 年度财务决算报告的议案 | 7 | | 议案三：关于公司 | 2023 | 年度利润分配预案的议案 | 8 | | 议案四：关于公司 | 2023 | 年年度报告及摘要的议案 | 9 | | 议案五：关于公司 | 2024 | 年度董事薪酬的议案 | 10 | | 议案六：关于公司 | 2024 | 年度对外担保预计的议案 | 11 | | 议案七：关于公司 | 2023 | 年度监事会工作报告的议案 | 12 | | 议案八：关于公司 | 2024 | 年度监事薪酬的议案 | 13 | | | | 议案九：关于变更公司注册资本、 ...